CTXR
Healthcare BiotechnologyCitius Pharmaceuticals, Inc.
$0.52
-0.02 -3.70% today
Price History
Not enough data
Key Stats
Market Cap
14.28M
Avg Volume
526,190
EPS
-$1.75
52W High
$2.19
52W Low
$0.47
Div. Yield
0.0%
Analyst Ratings
Buy0
Str Buy
1
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-0.36
P/B Ratio
0.21
P/S Ratio
2.01
EV/Revenue
1.93
Margins
Gross Margin 77.3%
Operating Margin (670.2%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(81.1%)
Return on Assets
(26.6%)
Liquidity & Leverage
Current Ratio
0.84
Quick Ratio
0.34
Debt / Equity
0.09
Total Cash
17.01M
Total Debt
7.18M
About
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
citiuspharma.com